<DOC>
	<DOCNO>NCT02592499</DOCNO>
	<brief_summary>The study prospective , randomize , non-blinded , national , multi-center study . The study consist assignment eligible patient treatment either HeartMate III ( HM III ) leave ventricular assist device system pharmacological treatment ( optimal medical management , OMM ) accord current guideline . One hundred forty ( 140 ) patient enrol study randomize 1:1 fashion HM III OMM .</brief_summary>
	<brief_title>Swedish Evaluation Left Ventricular Assist Device Permanent Treatment End-stage Heart Failure</brief_title>
	<detailed_description>The primary objective compare survival leave Ventricular Assist Device ( LVAD ) destination therapy optimal medical management Swedish end stage heart failure population ineligible cardiac transplantation . The secondary objective compare treatment group respect organ function , functional capacity , quality life adverse event . All patient enrol study follow 2 year . Patients continue go HM III OMM past 2 year continue follow outcome adverse event 5 year . Patient recruitment expect occur 24 month . The study conduct Sweden 7 University Hospitals implantation perform 5 site .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Signed informed consent 2 . Adult ( ≥ 18 year ) 3 . Chronic heart failure ≥ 45 day . 4 . Left ventricular ejection fraction ≤ 30 % . 5 . NYHA IIIBIV , INTERMACS profile 26 6 . At least 2 4 adverse prognostic criterion : SHFM estimate 1year survival ≤75 % NTproBNP ≥ 2000 ng/l VO2 max &lt; 14 ml/kg/min &lt; 50 % predict VO2max attainment anaerobic threshold ( AT ) , unable perform . Need continuous intermittent inotropic support &gt; 2 hospitalization last 6 month . 7 . Receiving medical management optimal dose betablockers , ACEinhibitors ARBs , MRAs least 30 day tolerate . 8 . Receiving CRT indicate least 45 day . 9 . Receiving ICD indicated appropriate . 10 . Ineligible cardiac transplantation ( e.g . high age and/or comorbidities ) 11 . Considered suitable study multidisciplinary board 1 . Eligible heart transplantation likely become eligible VAD treatment ( bridgetocandidacy ) 2 . Indication revascularisation , valvular surgery cardiac intervention expect improve cardiac function prognosis ( CABG , PCI TAVI , mitraclip etc . ) 3 . INTERMACS profile 1 `` crash burn '' 4 . Ongoing mechanical circulatory support . 5 . Heart failure due restrictive cardiomyopathy pericardial disease , active myocarditis uncorrected thyroid disease . 6 . Untreated aortic aneurysm &gt; 5 cm . 7 . Mechanical aortic valve convert bioprosthesis patch 8 . Moderate severe aortic insufficiency without plan correction 9 . Technical obstacle , pose inordinately high surgical risk 10 . Active , uncontrolled infection 11 . Stroke within 90 day carotid artery stenosis &gt; 80 % 12 . Significant peripheral vascular disease . 13 . Severe COPD severe restrictive lung disease . 14 . Intrinsic hepatic disease define liver enzyme value ( AST ALT total bilirubin ) &gt; 5 time upper limit normal , INR &gt; 2.0 , due anticoagulant therapy . 15 . Intolerance anticoagulant antiplatelet therapy operative therapy patient require base upon patient 's health status . 16 . Platelet count &lt; 50,000 . 17 . Measured GFR &lt; 20 ml/min/1.73m2 unresponsive inotrope treatment chronic dialysis . 18 . High risk right ventricular failure accord echocardiography and/or invasive hemodynamic measurement include least one following : 1 . Severe TI 2 . TAPSE &lt; 0.72 cm 3 . RVEDD/LVEDD &gt; 0.72 4 . CVP &gt; 16 mm Hg 5 . MPAP RAP &lt; 10 mmHg SPAPDPAP/CVPm &gt; 1 ok , &lt; 0.5 bad , borderline 6 . CVP/PCWP &gt; 0.63 7 . RVSWI &lt; 300 mm Hg x ml/m2 8 . Bilirubin &gt; 34 micromol/L 19 . Body Mass Index ( BMI ) &gt; 40 kg/m2 . 20 . Psychiatric disease , cognitive dysfunction , alcohol drug abuse , psychosocial issue likely impair study compliance 21 . Female childbearing age positive pregnancy test willing use adequate contraceptive precaution study . 22 . Condition , heart failure , could limit survival less 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HM III</keyword>
	<keyword>survival</keyword>
	<keyword>LVAD</keyword>
</DOC>